Placebo News and Research

RSS

Paracetamol does not meet minimum standard of clinical effectiveness in osteoarthritis patients

In a large-scale analysis of pain-relief medication for osteoarthritis, researchers found that paracetamol does not meet the minimum standard of clinical effectiveness in reducing pain or improving physical function in patients with knee and hip osteoarthritis.

18 Mar 2016

Findings could be final puzzle piece in developing effective dengue vaccine

In a small clinical trial led by the Johns Hopkins Bloomberg School of Public Health, researchers say that a promising single-dose dengue vaccine, developed by scientists at the National Institutes of Health, was 100 percent effective in preventing human volunteers from contracting the virus, the most prevalent mosquito-borne virus in the world.

18 Mar 2016

USF receives $9 million NIH grant to study unique treatment for age-related hearing loss

Researchers in the University of South Florida's Global Center for Hearing and Speech Research, recognized as the world's top research center for age-related hearing loss, have received a five-year, $9 million grant from the National Institutes of Health to study two unique ways to treat age-related hearing loss (ARHL).

17 Mar 2016

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in previously untreated metastatic pancreatic cancer patients.

16 Mar 2016

Could prebiotics benefit early life brain development? An interview with Dr Phil Burnet

Galacto-oligosaccharides are essentially sugar or saccharide molecules that have been joined together into short polymer chains.

16 Mar 2016

Mindfulness meditation reduces pain without endogenous opioid system

Everyone knows that stubbing your toe hurts. What makes it stop hurting is the body's main pain-blocking process - the natural production of opioids.

16 Mar 2016

Omega-3 fatty acids improve cognitive function in older adults

Changes in cognitive function and memory decline form a normal part of aging. However, in neurodegenerative diseases such as Alzheimer's disease or mild cognitive impairment (the pre-dementia phase of Alzheimer's disease), these changes occur more quickly. There are currently no effective treatments for these diseases.

16 Mar 2016

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe.

15 Mar 2016

ZYTIGA plus prednisone provides overall survival benefit in men with early and less aggressive mCRPC

Janssen-Cilag International NV today announced that data from a post-hoc analysis of the Phase 3 COU-AA-302 trial showed that ZYTIGA (abiraterone acetate) plus prednisone provided an 11.8 months overall survival (OS) benefit (53.6 months vs 41.8 months; HR = 0.61 [95% CI, 0.43-0.87]; p = 0.0055), compared to an active control of placebo plus prednisone, in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

15 Mar 2016

BioSpecifics reports net income of $2.7 million for fourth quarter 2015

BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX in the U.S. and Xiapex in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update.

14 Mar 2016

Blueberries can have a real benefit in lowering risk of heart disease, cancer and Alzheimer's

The blueberry, already labeled a "super fruit" for its power to potentially lower the risk of heart disease and cancer, also could be another weapon in the war against Alzheimer's disease. New research being presented today further bolsters this idea, which is being tested by many teams.

14 Mar 2016

Research findings could help treat people with sexual disorders

Undesirable associations with sex can be unlearned, but return if the circumstances change. They must therefore be unlearned in different situations. The drug D-cycloserine may help here. These are the findings of psychologist Mirte Brom.

11 Mar 2016

Love hormone may enhance compassion of people suffering from PTSD symptoms

Oxytocin - "the love hormone" - may enhance compassion of people suffering from symptoms of post-traumatic stress disorder (PTSD), according to new study conducted at the University of Haifa and Rambam Health Care Campus: "The fact that the present study found, that Oxytocin may improvement compassion among patients with post-traumatic stress disorder toward women, provides new evidence that oxytocin may be able to improve the social behavior of these patients," said Professor Simone Shamay-Tsoory from the Department of Psychology at the University of Haifa, who led the study.

11 Mar 2016

Popular kidney cancer drugs do not reduce incidence of recurrence

Two widely used targeted therapy drugs approved by the FDA for the treatment of metastatic kidney cancer—sorafenib and sunitinib—are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to a new multi-institutional study in the Lancet led by a researcher at the Abramson Cancer Center (ACC) of the University of Pennsylvania.

10 Mar 2016

Changes in gut bacteria strongly associated with PCOS-related obesity

Modifying gut bacteria could be a treatment option for some of the symptoms associated with the widespread disease polycystic ovary syndrome (PCOS), according to a recent study by San Diego State University researchers in collaboration with investigators from the University of California, San Diego.

8 Mar 2016

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Eli Lilly and Company announced today that patients with moderate-to-severe plaque psoriasis who did not respond to treatment with etanercept achieved significant improvement in their psoriasis plaques when treated with ixekizumab in a Phase 3 clinical trial. Detailed results of the UNCOVER-2 study were presented during the American Academy of Dermatology Annual Meeting taking place March 4-8 in Washington, D.C.

8 Mar 2016

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD).

8 Mar 2016

BetterYou’s DLuxPregnancy oral spray could boost vitamin D levels of expectant mums

An innovative way of boosting the vitamin D levels of expectant mums could help to improve their babies’ bone health, say health pioneers BetterYou.

From BetterYou Ltd 7 Mar 2016

New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib).

7 Mar 2016

Vitamin D supplements during pregnancy do not improve babies' bone health, but may have seasonal effect

Taking vitamin D supplements during pregnancy, as recommended for all women under UK guidelines, has no significant effect on the bone density of babies, according to the first randomised controlled trial of its kind, published in The Lancet Diabetes & Endocrinology journal.

7 Mar 2016

Placebo News and Research

Paracetamol does not meet minimum standard of clinical effectiveness in osteoarthritis patients

Findings could be final puzzle piece in developing effective dengue vaccine

USF receives $9 million NIH grant to study unique treatment for age-related hearing loss

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

Could prebiotics benefit early life brain development? An interview with Dr Phil Burnet

Mindfulness meditation reduces pain without endogenous opioid system

Omega-3 fatty acids improve cognitive function in older adults

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

ZYTIGA plus prednisone provides overall survival benefit in men with early and less aggressive mCRPC

BioSpecifics reports net income of $2.7 million for fourth quarter 2015

Blueberries can have a real benefit in lowering risk of heart disease, cancer and Alzheimer's

Research findings could help treat people with sexual disorders

Love hormone may enhance compassion of people suffering from PTSD symptoms

Popular kidney cancer drugs do not reduce incidence of recurrence

Changes in gut bacteria strongly associated with PCOS-related obesity

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

BetterYou’s DLuxPregnancy oral spray could boost vitamin D levels of expectant mums

New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

Vitamin D supplements during pregnancy do not improve babies' bone health, but may have seasonal effect

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News